Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALGS NASDAQ:LSTA NASDAQ:MTEX NASDAQ:PYRGF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALGSAligos Therapeutics$4.22+3.5%$5.50$3.98▼$13.69$26.13M2.26161,195 shs25,202 shsLSTALisata Therapeutics$1.30-9.8%$3.26$1.29▼$5.07$11.71M0.79137,047 shs109,723 shsMTEXMannatech$4.74-6.7%$5.10$3.80▼$12.45$9.15M0.7222,802 shs4,787 shsPYRGFPyroGenesis Canada$0.13-1.4%$0.17$0.12▼$0.53$31.76M0.2453,132 shs38,560 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALGSAligos Therapeutics0.00%-22.73%-26.75%-35.14%-55.31%LSTALisata Therapeutics-13.77%-59.21%-57.14%-55.00%-46.47%MTEXMannatech+12.89%+19.53%+0.20%+10.68%-36.93%PYRGFPyroGenesis Canada-0.90%-0.08%-8.78%-52.04%-55.44%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALGSAligos Therapeutics$4.22+3.5%$5.50$3.98▼$13.69$26.13M2.26161,195 shs25,202 shsLSTALisata Therapeutics$1.30-9.8%$3.26$1.29▼$5.07$11.71M0.79137,047 shs109,723 shsMTEXMannatech$4.74-6.7%$5.10$3.80▼$12.45$9.15M0.7222,802 shs4,787 shsPYRGFPyroGenesis Canada$0.13-1.4%$0.17$0.12▼$0.53$31.76M0.2453,132 shs38,560 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALGSAligos Therapeutics0.00%-22.73%-26.75%-35.14%-55.31%LSTALisata Therapeutics-13.77%-59.21%-57.14%-55.00%-46.47%MTEXMannatech+12.89%+19.53%+0.20%+10.68%-36.93%PYRGFPyroGenesis Canada-0.90%-0.08%-8.78%-52.04%-55.44%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALGSAligos Therapeutics 2.86Moderate Buy$38.50811.46% UpsideLSTALisata Therapeutics 1.67Reduce$15.001,054.73% UpsideMTEXMannatech 1.00SellN/AN/APYRGFPyroGenesis Canada 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest MTEX, ALGS, PYRGF, and LSTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026LSTALisata Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026MTEXMannatech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)7/10/2026ALGSAligos Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/1/2026MTEXMannatech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/25/2026ALGSAligos Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/11/2026MTEXMannatech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/29/2026ALGSAligos Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/28/2026ALGSAligos Therapeutics Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.005/26/2026MTEXMannatech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/21/2026ALGSAligos Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$20.005/21/2026ALGSAligos Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$20.00(Data available from 7/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALGSAligos Therapeutics$4.71M5.56N/AN/A$8.67 per share0.49LSTALisata Therapeutics$170K69.61N/AN/A$1.66 per share0.78MTEXMannatech$108.04M0.08N/AN/A($2.75) per share-1.72PYRGFPyroGenesis Canada$9.14M3.47N/AN/A($0.01) per share-13.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALGSAligos Therapeutics-$24.19M-$8.69N/AN/AN/A-1,919.68%-139.47%-90.88%8/5/2026 (Estimated)LSTALisata Therapeutics-$16.59M-$1.86N/AN/AN/AN/A-103.54%-83.08%8/6/2026 (Estimated)MTEXMannatech-$15.21M-$6.71N/AN/AN/A-11.97%-2,383.34%-40.24%N/APYRGFPyroGenesis Canada-$21.12M-$0.04N/AN/AN/A-115.14%N/A-60.81%N/ALatest MTEX, ALGS, PYRGF, and LSTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2026Q2 2026ALGSAligos Therapeutics-$1.41N/AN/AN/A$24.68 millionN/A5/14/2026Q4 2025MTEXMannatechN/A$0.49N/A$0.49N/A$24.92 million5/11/2026Q1 2026LSTALisata TherapeuticsN/A-$0.50N/A-$0.50N/AN/A5/7/2026Q1 2026ALGSAligos Therapeutics-$2.29-$2.21+$0.08-$2.21$0.25 million$2.83 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALGSAligos TherapeuticsN/AN/AN/AN/AN/ALSTALisata TherapeuticsN/AN/AN/AN/AN/AMTEXMannatechN/AN/A-100.00%N/AN/APYRGFPyroGenesis CanadaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALGSAligos TherapeuticsN/A2.562.56LSTALisata TherapeuticsN/A4.234.23MTEXMannatechN/A1.090.59PYRGFPyroGenesis CanadaN/A0.600.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALGSAligos Therapeutics60.43%LSTALisata Therapeutics8.94%MTEXMannatech12.98%PYRGFPyroGenesis Canada0.03%Insider OwnershipCompanyInsider OwnershipALGSAligos Therapeutics7.80%LSTALisata Therapeutics9.10%MTEXMannatech47.50%PYRGFPyroGenesis Canada47.68%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALGSAligos Therapeutics906.19 million5.71 millionNo DataLSTALisata Therapeutics309.11 million8.28 millionNot OptionableMTEXMannatech2501.93 million1.01 millionNot OptionablePYRGFPyroGenesis Canada90244.28 million96.34 millionNo DataMTEX, ALGS, PYRGF, and LSTA HeadlinesRecent News About These CompaniesPyroGenesis Canada (NASDAQ:PYRGF) and Gemini Therapeutics (NASDAQ:GMTX) Head-To-Head SurveyJuly 27 at 2:15 AM | americanbankingnews.comPyroGenesis Reports Voting Results From 2026 Meeting of ShareholdersJune 23, 2026 | globenewswire.comPyroGenesis Delivers New Technology to Convert Contaminated Biomass to SyngasJune 17, 2026 | globenewswire.comP. Peter Pascali Updates Early Warning ReportJune 8, 2026 | globenewswire.comPyroGenesis Announces Closing of $2 Million Private PlacementJune 4, 2026 | globenewswire.comPyroGenesis Announces Closing of $6.26 Million in FinancingsJune 3, 2026 | globenewswire.comPyroGenesis Announces Upsize of Bought Deal LIFE Offering to $3.7 MillionMay 20, 2026 | globenewswire.comPyroGenesis Announces $3.0 Million Bought Deal LIFE Offering and Concurrent CEO Private Placement of up to $2.0 MillionMay 19, 2026 | newsfilecorp.comNPyroGenesis Announces a Binding Signed Contract to Acquire its Turcot Manufacturing FacilityMay 14, 2026 | globenewswire.comPyroGenesis Announces First Quarter 2026 Results: Revenue of $4.9 Million, Up 63% ...May 7, 2026 | caledonianrecord.comCPyroGenesis Announces First Quarter 2026 Results: Revenue of $4.9 Million, Up 63% Year-Over-Year for Best Quarter Since 2022May 7, 2026 | globenewswire.comPyroGenesis Schedules 2026 First Quarter Financial Results and Business Update Conference CallMay 1, 2026 | globenewswire.comPyroGenesis Provides Corporate Update on NexGen™ Titanium Metal Powder StrategyApril 29, 2026 | globenewswire.comPyroGenesis Announces Appointment of Jean Mayer as Vice-President, Legal Affairs and Corporate SecretaryApril 28, 2026 | globenewswire.comPyroGenesis Produces Battery-Grade Graphite from Carbon Black Using Proprietary Plasma SystemApril 23, 2026 | globenewswire.comPyroGenesis Announces Fourth Quarter and Full Year 2025 ResultsMarch 30, 2026 | globenewswire.comPyroGenesis Announces Closing of Non-Brokered Private PlacementMarch 26, 2026 | globenewswire.comPyroGenesis Schedules 2025 Fiscal Year Financial Results and Business Update Conference CallMarch 23, 2026 | globenewswire.comPyroGenesis Announces Oversubscription of Non-Brokered Private PlacementMarch 11, 2026 | globenewswire.comPyroGenesis Announces $1 Million Non-Brokered Private PlacementMarch 9, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMTEX, ALGS, PYRGF, and LSTA Company DescriptionsAligos Therapeutics NASDAQ:ALGS$4.22 +0.14 (+3.53%) As of 12:34 PM Eastern This is a fair market value price provided by Massive. Learn more.Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Lisata Therapeutics NASDAQ:LSTA$1.30 -0.14 (-9.79%) As of 12:34 PM Eastern This is a fair market value price provided by Massive. Learn more.Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.Mannatech NASDAQ:MTEX$4.74 -0.34 (-6.69%) As of 11:06 AM EasternMannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.PyroGenesis Canada NASDAQ:PYRGF$0.13 0.00 (-1.44%) As of 11:27 AM EasternPyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amkor Sells Off After Earnings—Why Weak Guidance Isn't the Real Story Nano Nuclear’s Air Force Contract Puts Its Short-Squeeze Setup in Focus 5 Space Stocks Face a Brutal Correction: Which Ones Are Still Buys? Is the Market Mispricing ServiceNow's AI Future? Whirlpool’s Report May Show How Frozen the Housing Market Really Is 3 Stocks Standing Out and 2 Losing Momentum as the Tech Rally Cracks 5 AI Stocks Are Pulling Back—Which Growth Catalysts Still Look Strongest? Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
